Articles tagged with Drug Targets
A new discovery could lead to modified thiazolidinediones with fewer side effects, benefiting more patients with diabetes. Activating only PPARγ2 eliminates the risk of weight gain while maintaining anti-diabetic effects.
Researchers have solved the full-length structure of a crucial signaling protein in cells, known as a Janus kinase. The breakthrough could lead to new and better drugs against certain cancers, allowing healthy versions of the proteins to keep performing their normal duties.
A UC Riverside-led team developed a theory and performed simulations to understand how viruses package their genetic material. The research reveals that capsid proteins are inclined to form shells around viral RNAs due to lower stress distribution, which can aid in designing nanocontainers for drug delivery.
The new laboratory will use microfluidics, AI, and machine learning to conduct thousands of parallel experiments on single-cell eukaryotic yeast and other microbes. This will simplify the study of biology and provide a pathbreaking 'robot scientist' for fundamental research.
Researchers have identified a crucial nuclear transport mechanism essential for organ growth and development, involving the protein YAP. The study shows that YAP interacts with importin-7 to control its nuclear entry, regulating cell and tissue growth, and potentially targeting diseases such as atherosclerosis and cancer.
Researchers from CCDC, Exscientia, and Oxford University have developed an automated method for informing the design of compound selectivity across protein families. The 'Hotspot API' uses ensemble hotspot maps to quantify the propensity for compounds to exploit interactions in preferred binding sites.
A University of Cincinnati clinical trial showed promising results for patients with intermediate risk head and neck cancer when an immunotherapy drug, pembrolizumab, was added to standard treatment regimens. The study found improved one-year disease-free survival rates compared to historical controls.
The article suggests a potential treatment option for COVID-19 by targeting SARS-CoV-2's interaction with ACE2 receptors. Combining DPP4 inhibitors and spironolactone may mitigate COVID-19 complications and infections without adverse side effects.
Researchers at the University of Houston have identified a new biomarker, NPY1R, that predicts therapy outcome and has potential as a drug target in estrogen receptor-positive breast cancer. The study found that NPY1R expression is associated with favorable outcomes in Luminal A subtype breast cancer, but declines in resistant cases.
Scientists have devised a method to pinpoint active ingredients from traditional Chinese medicine formulations, revealing 4 analytes with significant anti-inflammatory activity. This breakthrough could improve quality control standards and lead to better herbal remedies.
Codiak BioSciences' exoASO-STAT6 demonstrates potent anti-tumor efficacy by reprogramming tumor-associated macrophages to an M1 phenotype, showing promise as a monotherapy candidate for hepatocellular carcinomas and other cancers. The company plans to initiate Phase 1 clinical trials in the first half of 2022.
Researchers discovered how a single mutation in an enzyme enables bacteria to evade antibiotics by using mirrored structures. This finding has implications for developing more resilient inhibitors and proactive drug designs.
Researchers at UC San Diego have made a groundbreaking discovery about the role of fibroblasts, or fat cells, in controlling bacteria and developing acne. These findings could lead to more targeted treatment options for acne, which affects up to 50 million Americans each year.
A new protein group has been identified that functions as a switch to regulate biological activity, found in all domains of life and essential for cellular activities such as gene expression and metabolism. The discovery opens up new possibilities for the development of novel drugs targeting these switches.
Researchers at the University of Toronto have identified hundreds of new proteins associated with cystic fibrosis, including those that interact with the CFTR protein. These discoveries may shed light on why some patients respond better than others to current therapies.
Researchers adapted cancer models to predict effective drug combinations for treating Covid-19 at different stages of the disease. The study identified existing therapeutics that might be suitable for treating severe cases, and could help lower Covid-19 related deaths.
Researchers at Oregon State University have discovered a new class of potential drug targets for neurodegenerative conditions like Alzheimer's and Parkinson's. Oxidized proteins, such as Hsp90, can trigger cell death, and targeting these molecules may slow illness progression without side effects.
Scientists have identified connexin (Cx) 43 hemichannels on the surface of bone cells as a potential new target for medications to treat osteoporosis and other conditions that cause bone loss. The study, published in eLife, reveals how these channels play a crucial role in responding to mechanical stress and building stronger bones.
Researchers found that disulfiram protected rodents from immune-mediated lung injury in models of SARS-CoV-2 coronavirus infection and TRALI, a rare lung failure syndrome. Disulfiram blocks NETs formation, which can cause lung damage and blood clots.
A new generation of cholesterol-lowering drugs is being developed to target the PCSK9 protein, which regulates LDL receptor degradation on cells. These therapies have shown promise in reducing LDL levels with fewer side effects than statins.
A recent study found an increase in intentional drug overdose deaths among young people aged 15-24, older adults aged 75-84, and non-Hispanic Black women. Despite a downward trend in overall deaths, these subgroups saw a rise in intentional overdose death rates, with women ages 45 to 64 having the highest rates.
Scientists have identified a key receptor in the digestive tract that triggers pain and inflammation in the colon. By blocking this receptor from entering cells, researchers found significant reduction in pain and inflammation. This discovery holds promise for treating inflammatory bowel disease.
A study led by Clemson University geneticist Allison Hickman has identified 11 high-priority genes associated with uterine cancer. These genes are potential targets for drug therapies, offering new hope for effective treatment options.
Researchers developed a new method to screen drugs for treating Alzheimer's disease, shedding light on why current treatments have been ineffective. The study identified new targets for drug development by analyzing disease mechanisms in human neurons.
A new study by WVU researcher William Walker found that the blood-brain barrier is dynamic and more receptive to chemotherapy at night. This could lead to better treatment outcomes for patients with brain metastasis.
Researchers have discovered that a bacteria-fighting mechanism in the immune system, NETs, can manipulate beneficial Th17 cells into harmful autoimmune responders. This finding opens doors to developing targeted therapies for multiple sclerosis and other autoimmune conditions.
Researchers at Rice University and Baylor College of Medicine have created an antibody with an engineered peptide that effectively targets and attacks bone tumors in breast cancer. The study shows the therapeutic efficacy is best when a moderate amount of the drug compound is delivered, offering new hope for treating bone metastases.
Researchers discovered that the IL-6 family of proteins is required for maintaining and regenerating cartilage in joints and growth plates. The study found that blocking this gene could lead to severe cartilage and skeletal changes, particularly in females.
Researchers at La Jolla Institute for Immunology found that macrophages in artery walls can sense octanal, leading to inflammation and atherosclerosis. By blocking this detection, they reversed disease progression. Further research is needed to explore the role of olfactory receptors in cardiovascular diseases.
A new study sheds light on the molecular interactions between remdesivir and various viruses, revealing why it works against SARS-CoV-2 but not others like influenza. The findings aim to develop broad-spectrum therapies for future pandemics.
Researchers at Cold Spring Harbor Laboratory discovered a previously unknown protein called SCP4 that plays a crucial role in the survival of acute myeloid leukemia cells. The study found that SCP4 can pair with specific kinases to regulate cell activity, and targeting this pathway may lead to effective treatment options.
A study found that cholinesterase inhibitors like donepezil increase the risk of overactive bladder in people with dementia. Galantamine and rivastigmine were not associated with this increased risk.
Researchers developed a new class of nanomaterials that capture chemotherapy drugs before they interact with healthy tissue, reducing off-target effects. The highly efficient approach captures DOX at a capacity more than 3,200% higher than other platforms.
Researchers have found that blocking mineralocorticoid receptors, a key factor in bone health, may help protect against bone loss and osteoporosis. This new target is thought to be more effective than previously believed logical targets, such as reducing glucocorticoid receptor activity.
A new study suggests that combining two drugs can reduce postoperative opioid use and side effects in adolescents with scoliosis. The combination of intrathecal morphine and oral gabapentin provides more effective pain control, resulting in fewer side effects and lower narcotic consumption.
Researchers at UC Riverside have discovered that targeting the TNFR1 receptor may be a more effective approach to treating inflammatory bowel disease. By selectively blocking TNFR1, they found significant benefits in mice with Crohn's-like ileitis, suggesting this approach could offer a new opportunity for healing.
The reNEW Center aims to harness therapeutic potential in stem cell medicine for incurable diseases, with a focus on translation and collaboration. Scientists will work together to develop new treatments and therapies.
Researchers used PET scans to quantify antibiotic levels in orthopaedic implants, discovering rifampin penetration is only about 14% as much as previously believed. A higher dose of rifampin achieved higher bacterial killing and fewer antibiotic-resistant strains, suggesting a shorter treatment regimen may be effective.
Researchers at Houston Methodist have discovered a new combination therapy that regresses tumor growth of triple negative breast cancer and prevents the cancer from spreading. The response rate using this therapy is about 50%, compared to 25-30% with older drugs, offering new hope for patients with hard-to-treat breast cancers.
Scientists have discovered a new potential treatment to reverse antibiotic resistance in bacteria causing sepsis, pneumonia, and urinary tract infections. The indole carboxylates class of enzyme blockers can stop MBL resistance enzymes from working, allowing antibiotics like carbapenems to effectively target bacteria.
Cancer cells secrete type III collagen to stay dormant, and when levels decrease, they wake up and create metastatic cancer. Researchers found that enriching the environment with collagen can force cells to remain in a dormant state and prevent tumor recurrence.
Researchers have mapped the atomic structure of amphotericin B, a powerful but toxic antifungal agent. The detailed structure reveals how the drug kills fungal cells by robbing them of sterol molecules, providing a roadmap for synthesizing less-toxic derivatives.
Researchers identified three prototypical RNA-expression states in pancreatic cancer cells and found that altering the tumor microenvironment can drive tumor cells to become more susceptible to certain drugs. This discovery opens up new possibilities for personalized medicine and targeting specific drug responses.
An experimental drug called NAP has been found effective in treating a broad spectrum of symptoms related to autism, intellectual disability, and Alzheimer's disease. Researchers discovered that NAP normalizes brain function in mice modeling ADNP syndrome, a rare disorder linked to these conditions.
The study, published in Nature Aging, found that sildenafil reduces the likelihood of developing Alzheimer's disease by 69% compared to non-users. Sildenafil also shows promise in treating the disease by increasing brain cell growth and decreasing hyperphosphorylation of tau proteins.
Jpx RNA regulates CTCF anchor site selection and formation of chromosome loops, determining gene expression. This discovery may lead to new treatments for diseases influenced by chromatin looping.
A research team developed an AI framework that analyzes protein interactions to predict effective and low-toxicity cancer drug combinations. The framework, GraphSynergy, outperforms conventional models in identifying synergistic combinations.
A new study has identified a promising drug candidate to minimize uncontrolled muscle movements associated with Parkinson’s disease. PD13R reduced dyskinesia by more than 85% in animal studies, also improving sleep quality compared to other treatments.
Researchers have discovered that certain molecules inhibiting thioredoxin reductase (TrxR) have a more specific effect than gold-based therapy auranofin. TRi-1 and TRi-2 compounds show promise as anticancer drugs, with higher specificity in their inhibition of TrxR.
A functional precision medicine study demonstrates that treatment selection based on results from drug sensitivity testing can be clinically useful in patients with aggressive hematological cancer. The approach combines deep molecular profiling with comprehensive drug sensitivity testing to advance the therapy decision-making system.
Researchers have used advanced microscopy to study the ultrastructure of huntingtin inclusions, revealing different mechanisms of aggregation that lead to distinct biochemical properties. The findings suggest targeting inclusion growth as a potential therapeutic strategy for slowing Huntington's disease progression.
Scientists discovered an important protective response in the heart that can prevent excessive scarring after a heart attack. The study found that this reactive response can limit cardiac fibrosis by preventing oxidant build-up in heart cells, potentially leading to new therapies to repair scarring damage.
Researchers at Vanderbilt University have identified a new target for rapid antidepressant drugs using ketamine's role in synaptic effects. This breakthrough could lead to new treatments for approximately half of patients whose current antidepressants are ineffective, significantly reducing the risk of suicide.
A study at Weill Cornell Medicine reveals how drugs can affect membrane-spanning proteins, causing unwanted side effects. The researchers found that membrane-associated drugs can interact with these proteins in multiple ways, leading to changes in membrane characteristics.
St. Jude researchers have identified a possible risk for late effects of treatment with the experimental cancer drug CX-5461, which targets topoisomerase II beta (TOP2β) instead of RNA polymerase 1. The study highlights the need for close monitoring of patients enrolled in ongoing clinical trials.
Researchers at West Virginia University have received FDA approval for a new drug to treat uveal melanoma, a rare form of eye cancer. The drug, MTI-201, targets specific biomarkers in diseased cells, allowing for more precise treatment with minimal damage to healthy cells.
A study at the University of São Paulo found that Torquetenovirus (TTV) titer is higher in people infected by SARS-CoV-2, suggesting it could be a biomarker for COVID-19 severity. TTV load correlates with disease progression and outcome, and its measurement may support diagnosis.
A team of experts from Tel Aviv University has identified 5 coronavirus proteins responsible for damaging blood vessels. The researchers hope that the identification will lead to the development of targeted drugs that reduce vascular damage in COVID-19 patients.
Researchers developed a new online portal, DINC-COVID, to speed up the identification of potential pandemic treatments. The platform incorporates models of three drug targets and uses ensemble docking to score ligands' success in binding.
A clinical trial of 465 patients found that administering heparin in therapeutic doses reduced mortality from COVID-19 by 78%, with benefits only observed when administered between seven and 14 days after symptom onset. The study suggests that timing is crucial for treatment efficacy.